The Pressure is On: Managing Challenging Cases in Glaucoma

> Mark T. Dunbar, OD, FAAO Bascom Palmer Eye Institute Miami, FL

#### Mark Dunbar OD: Financial Disclosure · Optometry Consultant · Advisory Board for: - Carl Zeiss - Allergan - Allergan Carl Zeiss - Regeneration - Regeneron - Genentech Mark Dunbar does not own stock in any of the above companie

## **Full Disclosure**

- Nothing I say in this lecture will have been an original thought
- I have shamelessly copied and pillaged almost every thought or concept discussed in this talk

General Principles in Glaucoma Management

- The higher the IOP, the greater the risk of acquiring glaucomatous damage and the greater the risk for progression
- There are factors other then IOP that contribute to ON damage and determine an individual susceptibility to harm from IOP
- At the moment, there is no effective treatment for glaucoma other then lowering IOP

3

4


2

What other factors besides IOP contribute to glaucomatous ON damage?


# 80 yo White Female


• Presented for "annual eye exam"

80 yrs old, female New Patient here for annual check Feels vision at distance was not as good as it has been, especially the LE She uses glasses to see small prints, reports good vision at distance OU. Denies pain, floaters or flashes of light. S/p. CEIOL OU, YAG laser posterior capsulotomy OD (Baptist Hospital) LEE: 02/2017 by M.D (w/DFE) Mom had glaucoma and used drops Generally does not wear glasses for driving









So now what? Is this low/normal tension glaucoma? Would you begin treatment today?

Would you begin treating on this visit? 1. Yes 3. I would refer to ophthalmologist

11 12

# This is what I did... Impression 1) Probable Normal Tension Glaucoma OU Inferior thinning OU Disc hemorrhage RE inferior OCT and GCC thin corresponding to clinical presentation TA ~ 15 OU 2) Pseudophakia OU 2) Pseudophakia OU 2) Pseudophakia Ed and reassure RTC 1-2 weeks for VF and IOP measurement Will start Tx at next visit Rx given for specs

A Few Thoughts on Disc Heme

13 14

In the OHTS Study what percentage of disc hemorrhages were MISSED by the doctor?

1. 24%

3) PVD OU

- 2. 44%
- 3. 64%
- 4. 84%

Detection and Prognostic Significance of Optic Disc Hemorrhages during the Ocular Hypertension Treatment Study

Donald L. Budenz, MD, MPH,<sup>1</sup> Douglas R. Anderson, MD,<sup>1</sup> William J, Fesser, MS,<sup>1</sup> Julix A. Betser, MS, Joyce Schiffman, MS,<sup>1</sup> Bichard K, Parrish II, MD,<sup>1</sup> Jody R, Piltz-Seymour, MD,<sup>1</sup> Mae O. Gordon, PhD,<sup>2</sup> Mchada A, Kan, MD,<sup>2</sup> Chadre Hopetransian Transment Vin.<sup>1</sup> Transment Vin.<sup>1</sup> Care

- Disc hemorrhages detected in 128 eyes of 123 participants
- 21 cases detected by both doctor and photos
- 107 cases (84%) were detected only by a review of photography

15

# Perhaps the Bigger Question?

- How is it that a patient can continue to "progress" or develop a disc hemorrhage with a pressure ~ 12?
- What are the factors that result in progression?

What other factors besides IOP contribute to glaucomatous ON damage?

• Blood pressure

16

- High vs Low blood pressure (BP)
- · Reduced ocular blood flow
  - Lower ocular perfusion pressure (OPPO
- Intracranial pressure (ICP)

17 18

#### Ischemia vs. Mechanical

- Ischemia: elevated IOP reduces blood flow to the optic nerve, thus creating chronic ischemia within the neural tissue
  - Local ischemia-hypoxia develops? dysfunction of blood flow autoregulation
- Mechanical: damage due to the mechanical affects of the elevated IOP
  - "Pressure" on the ON/Lamina
  - Ganglion cell axons undergo deformation and mechanical stress



Where Does Blood Pressure Fit In?

19


20

#### Where Does Blood Pressure Fit In?

- 1990's: Hayreh, Drance, and others 1st raised the important issues of systemic hypotension and nocturnal blood pressure dips in the progression of glaucoma
- The problem: difficult to measure systemic BP during sleeping hours

When is the highest IOP during the 24-hour cycle?

- IOP is a dynamic physiological parameter that doesn't remain constant over the course of 24 hours
- Trough IOP levels tend to occur at the end of the waking period
- Peak IOP is usually recorded at the end of the nocturnal sleep period



u JH, Kripke DF, Twa MD, et al. Twenty-four hour pattern of intraocular pressure in the aging

21

22

# **Risk Factors For Progression**


- BP is lowest at night
- IOP is highest during the night time
  - Highest prior to waking
- Combination of ↑ IOP and ♥ BP may result in a critical
   ♥ ocular perfusion pressure (OPP) in susceptible people
  - Patients with with faulty autoregulation

Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intracoular pressures in healthy subjects and glaucoma patients. An

### Ocular Perfusion Pressure (OPP)

- OPP is the relative pressure at which blood enters the eye
- Defined as the ocular arterial pressure minus the IOP
- OPP is a delicate balance between IOP and blood pressure
- Low ophthalmic perfusion pressure (OPP) is a risk factor for progression
  - Low BP and/or high IOP

MOPP = 2/3 X [DBP + 1/3 X (SBP - DBP)] - IOP Simple: Diastolic BP - IOP = OPP



Low OPP and Glaucoma Table 1 Low diastolic ocular perfusion pressure and prevalence of open-angle glaucoma Diastolic OPP <50-55 mmHg Study Prevalence: 2-6-fold
Prevalence: 3-fold only
in high-tension glaucoma\*
Prevalence: 4-fold
Prevalence: >3-fold
Prevalence: >4-fold only
in high-tension glaucoma
(mainly probable glaucoma) Baltimore Eye Survey Egna-Neumarkt Study 5308 4297 Proyecto VER Barbados Eye Study Rotterdam Eye Study (only participants receiving treatment for systemic hypertension) Adapted from [10-13,14\*\*]. OPP, ocular perfusion pressure. 
a Low OPP was defined as <68 mmHg in this study.


Risk Factors for Visual Field Progression in the Low-pressure Glaucoma Treatment Study

CARLOS GUSTAVO DE MORAES, JEFFREY M. LIEBMANN, DAVID S. GREENFIELD, STUART K. GARDINER, ROBERT RITCH, AND THEODORE KRUPIN, ON BEHALF OF THE LOW-PRESSURE GLAUCOMA TREATMENT STUDY GROUP

We determined that a lower MOPP during follow-up was significantly associated with visual field progression in our model and this effect was not significantly affected by other covariates, such as use of systemic antihypertensives and randomization arm (Table 4). An imbalance between Vascular Supply to the ON

26

- COMPLEX arterial supply and an even more complex venous drainage system
- Which vascular network is most critical for development of glaucoma?



27 28


### OPP and Glaucoma - The Reality

- Perfusion pressure is difficult to accurately measure
- · There is currently no widely accepted consensus regarding which techniques should be used to evaluate blood flow or how the results should be interpreted
- None of the methods used to estimate blood flow have been standardized or externally validated for humans
- Ocular blood flow measurements are not currently used in the diagnosis or management of patients with glaucoma



CSFp and Glaucoma

29 30



Cerebrospinal Fluid Pressure Is Decreased in Primary Open-angle Glaucoma John P. Berdahl, MD, <sup>1</sup> R. Rand Allingham, MD, <sup>1</sup> Douglas H. Johnson, MD<sup>2,†</sup> Index P. Berdeld, MD, <sup>1</sup> R. Rand Allingham, MD, <sup>1</sup> Drugler H. Johnson, MD<sup>2,2</sup>
Burguese: To company eventuropide half (ESF) pressure in patients with primary open-angle glaucoms DNAG, with that in monglaucomation patients.

PDAGIS with that in monglaucomation patients.

PDAGIS with that in monglaucomation patients.

Participants: Tritry-one thousand, seven handwad and sighty-sis subjects underwerd harbor punchure (LF)

Participants: Tritry-one thousand, seven handwad and sighty-sis subjects underwerd harbor punchure (LF)

Refineds: Retrospective review of residical records. Comparison of the 2 groups and factors associated with soft participants and of and anythrolium patients and of all residence in the seven anythrough the seven anythrough the seven anythrough the seven anythrolium patients and consideration use, relaction to P. Intracolour pressure (DF), polic date cup-to-disc ratio, visual field assessment, and CSF pressure and CSF pressure and the seven in PDAG patient in appareture of the patients. The major pressure difference (P-0.0001), and the transimisming researce difference (P-0.0001) and the transimisming researce difference (P-0.0001) and the transimisming researce difference (P-0.0001) and the stransimisming researce difference (P-0.0001) and the stransimisming researce difference (P-0.0001) and the stransimisming researce difference (P-0.0001). The patience of the

31 32

# Mayo Clinic Study: CSF and Glaucoma

- Retrospective review of 31,786 patients that had lumbar punctures over a 11-year period
- Determined # who had complete eye exams
- · 28 met inclusion criteria of POAG, 49 controls
- · ICP was significantly lower in patients with POAG compared to the non-glaucoma control

Berdahl JP, et al. Ophthalmology. 2008;115(5):763-768.

Berdahl 2nd Mayo Clinic Study: CSF and Glaucoma POAG vs. NTG vs OHT

- Retrospective review of 62,468 patients that had lumbar punctures over a 20-year period
- · 189 met inclusion criteria of complete eye exam
- ICP was significantly lower in patients with POAG and NTG and significantly higher in OHT

Berdahl JP, Fautsch MP, Stinnett SS, et al Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study. Invest Ophthalmol Vis Sci. 2008;49(12):5412-5418

33 34

#### Cerebrospinal Fluid Pressure in Glaucoma

A Prospective Study


Boojin Ren, MD,<sup>1,2</sup> Jost B, Josses, MD,<sup>1,4</sup> Guaglong Tian, MD,<sup>2</sup> Yi Zhen, MD,<sup>2</sup> Ke Ma, MD,<sup>1</sup> Shaning Li, MD,<sup>2</sup> Hongiao Wang, MD,<sup>2</sup> Bin Li, MD,<sup>1</sup> Xiaojini Zhang, MD,<sup>3</sup> Ningli Wang, MD


- Purpose: To seems whether a two continospinal fluid pressures (DSF-P) is associated with open-engle aucoma in you with normal intensitivity pressure (DSF-P) is associated with open-engle Purpositive Time (Park of the Purpositive Time (Park of the Park of t


Lumbar CSF Pressure in NTG, POAG and Non GL Ophthalmology Volume 117, Number 2, February 2010 Normal-Pressure Glaucema Group P-Value Glaucema Group P-Value Control Group <0.001 71 12.9±1.9


U test). If fluid pressure was statistically significant (P<0.001) also for the compari-group and the control group.

36 35












39 40


# Relationship between IOP and CSF


- In the normal state IOP and CSF have minimal trans-laminar pressure differences
- Increasing the difference alters the homeostatic balance and results pressure gradient difference at the lamina















45 46






47 48







**Glaucoma Today** (RESEARCH RESULTS) Cerebrospinal Fluid Pressure and Glaucoma Intracranial pressure may hold the key to understanding why IOP plays a major role in the development of glaucoma BY JOHN BERDAHL, MD

51 52

# Compromised Autoregulation in Glaucoma

- Autoregulation: The body's ability to regulate itself in the presence of change
  - Vascular factors
    - Cardiovascular disease Vasospasm
  - Postural changes


  - Atmospheric pressure
  - Temperature - Fatigue can lead to abnormal pressure-flow relationship
- · Periods of ischemia are then more likely to occur
  - Can result in reduced or fluctuating OPP


Autoregulation


Or Vascular Dysregulation...?


- Can lead to over/under perfusion
- Chronic under perfusion can lead to tissue necrosis and death
- · Unstable perfusion leads to oxidative stress

53 54










57 58



How Would You Mange This Patient? • Is the Normal Tension Glaucoma or POAG?

- Would you treat?
- What would be first line therapy
- Would you set a target IOP? - How low do you need to go?

59 60

# 51 y/o Hispanic Female Shadow in LE

- Lumigan 0.01 added qhs RE
- Returned 3 weeks later not aware of shadow – TA 12/17
- RTC 4 months


Case MC

- 73 yo female presents for follow up: GL Suspect
- Past history single elevated IOP
- BCVA 20/25 and 20/20
- IOP 21 RE 19 LE; - CCT 560u R 565u L
- Anterior segment normal
- Mild NS and cortical cataracts


61 62


The ON

- Small optic discs OU
- RE c/d ~ 0.6 but
  - Appeared saucerized infero temporally
  - Broadening of a vein as it crossed edge disc
  - ? Small disc hemorrhage
- LE c/d .35




63 64





65 66


4/13/21



Summary

- Suspicious disc
- Borderline IOP
- Normal visual field
- Normal OCT \*
- What would you do

67 68



This was her 15 months earlier

Is this Significant?

8/2012

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2013

10/2

69 70

Is that change significant?

How much change needs to occur on an OCT RNFL for it to be significant?

How much change needs to occur on an OCT RNFL for it to be significant?

- 5 microns
- 10 microns
- 20 microns
- 25 microns

Detecting Glaucoma Progression Using OCT - RNFL

RNFL Thinning on OCT
Patient able to do a
Reliable VF?

Is thinning 2.10 microns

No

Is the thinning 2.5 microns?

Progression not confirmed
Repeat studies at appropriate
Intervals

73 74

Fortunately, SDOCT measurements are highly reproducible.

Normal significance Limits
for Average RNFLT


• We can measure
multiple steps of
statistically significant
change while a
glaucoma suspect still
is in the green normal
range.

\*\*Proventile = 67 microns

\*\*Proventile = 67 microns

\*\*Total Clashing +50 microns

Values shown are for a 69 year old normal.



75 76

Estimating the Lead Time Gained by Optical Coherence Tomography in Detecting Glaucoma before Development of Visual Field Defects

Timery M. Kung, MD, \*\*\*\* Chemic Zhang, MD, \*\*\* Linds M. Zinguill, PhD, \*\* Robert N. Weineth, MD, Felge A. Moderno, MD, PhD

\*\*\*

\*\*\*Specificity, up to 35% of eyes had abrormal average FNPL thickness 4 years before development of visual field toos and 19% of eyes had abrormal results 8 years before field loss.

\*\*Correlations: A consequent of FNPL includes with OTC that able to defect glaucomatous denings before the appearance of visual field defects on SAP. In many subjects, significantly large loss! times were seen when applying OCT as an ancillary diagnostic tool. Optifisalmology 2015;\*\*:1—8 6 2015 by the American Academy of Ophthalmology.

Optical Coherence Tomography in
Detecting Glaucoma before Development
of Visual Field Defects


Tamery M. Kiung, MD. \*\*\*\*Channed Zhing, MD.\*\*\* Linda M. Zingsill, PMD.\*\* Raben N. Weimeb, MD.\*
Feldye A. Mediens, MD. \*\*PMD.\*\*\*


• At 95% specificity, up to 35% of eyes had abnormal average
RNFL thickness 4 years before development of visual field loss
and 19% of eyes had abnormal results 8 years before field loss.


• Conclusions: Assessment of RNFL thickness with OCT was able
to detect glaucomatous damage before the appearance of VF
defects on SAP. In many subjects, significantly large lead times
were seen when applying OCT as an ancillary diagnostic tool.

Estimating the Lead Time Gained by

77 78








# What Would You Do Now?

- · Obviously he needs a VF
- But would you start treatment now -> on THIS visit?

81 82

Would you treat Arturo on this initial visit with IOP 32/18 and normal OCT?

1. Yes
2. No



# Ocular Hypertension Treatment Study (OHTS)

- Long-term randomized, multicentered controlled, clinical trial
- 1500 OHT pts with moderate risk for POAG randomized
   Observation vs stepped medical therapy
- ♦ 5 yr minimum follow up
- ◆ Pts seen 2X/year for IOP check and HVF

### Ocular Hypertension Treatment Study (OHTS)

- ◆ 30-40 clinical centers
- Each center randomized minimum of 50 pts
- ♦ Men and women 40-80 yo
- ♦ IOF
  - ♦ ≥ 24, < 32 in 1 eye
    </p>
  - $\diamond \geq 21$ ,  $\leq 32$  in the fellow eye

85 86

OHTS: Arch Ophthalmol June 2002;120:701-713

- ◆ 1636 participants randomized, followed 60 mo
  - Observation vs Treatment
- ◆ Goal: Reduce IOP 20% or IOP < 24
  - Treatment: reduction 22.5% + 9.9%
  - \* Observation: reduction 4.0 + 11.6%
- Outcome: reproducible visual field defect or Reproducible optic disc deterioration

OHTS Results: Arch Ophthalmology June 2002;120:701-713

- ◆ Treatment reduced the chance of developing glaucoma by ≥ 50%
- ◆ The chance of developing POAG in 5 yrs:
  - ♦ Observation group: 9.5%
  - Treatment group: 4.4%
- ◆ Conclusion: Meds are effective in delaying or preventing the onset of POAG

87 88

#### African Americans and Glaucoma

(Archives of Ophthalmol; June 2004)

#### **African American Population**

- Risk of developing POAG doubled
  - \* Treated group: 8.4% developed POAG
  - \* Untreated group: 16.1% developed POAG
- ◆ Treatment lowered risk of glaucoma by almost 50%

Corneal Thickness and OHT


Arch Ophthal June 2002:;120:714-720

- Corneal thickness was a strong predictive factor
- Corneal thickness of < 555  $\mu$  had a 3X greater risk for developing POAG vs pts with thickness > 588  $\mu$ 
  - African Americans had 23.5  $\mu$  thinner corneas than other races closer to normal
  - Other races had thicker corneas than normal


89 90

#### OHT: 5 Yr Risk for POAG

- Baseline IOP of 25.75 mmHg
  - Ave Corneal thickness < 556  $\mu$ : 36% Risk
  - Corneal thickness 565 to 588  $\mu$ : 13%
- Cup-Disc ratio > 0.3
  - Ave Corneal thickness < 556  $\mu$ : 24%
  - Corneal thickness 565 to 588  $\mu{:}~16\%$



91



#### **Risk Factors POAG**

Arch Ophthal June 2002:;120:714-720

- Thin corneas
- Δσε
- Cup-disc ratio
- IOP

94

- Race but African Americans had thinner corneas and greater vertical C/D ratios
  - Sig in Univariate analyses (59% greater risk), not sig in multivariate analysis
- Reduced PSD at baseline (need multiple VF's)

93

# **Interpreting Risk**

- Expert consensus supports the following guidelines based on the 5-year risk of progressing from OHTN to POAG
  - < 5%: observe
  - 5%-15%: discuss with patient and consider treatment
  - > 15%: encourage treatment

OHTS 3: 20 Years: 2016 to 2019

- 66% Retention of study participants (1078 Pts) (Started with 1636 pts followed 1994 to 96)
  - 67% from the Med group
  - $-\,65\%$  from the observation group
  - 74% (833) there is IOP data (known pressure survivors)
    - 493 deceased (190 had OHTS visit before they died)
  - 1143 total survivors
- 30% (488 patients) developed glaucoma by 20 years

95 96

# 20 Years of OHTS

- 30% Developed POAG by 20 years?
  - Medication group: 220
  - Observation group: 266
- 64% developed POAG in only 1 eye
  - Largely a unilateral disease
- 36% developed POAG in 2 eyes
- 72% of those in the initial observation group ended up being on medication

OHTS: Putting it all together

- About 30% develop glaucoma over a 20 year period
- · Various risk factors increase may increase that % significantly
  - Older age
  - Thinner cornea
  - Higher IOP
- POAG conversion is largely unilateral
- Most patients with OHTN end up with treatment
  - The risk of converting to glaucoma is about that same as dying (more likely to occur in >70 yo)


97 98



Arturo


- Followed without treatment for 4-5 years
- Varying IOP's: Tmax 32/17
  - RE fluctuated 18 -> 29 (32 max on initial visit)


99 100





| 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 | 2013 |

101 102









105 106

# Arturo • Being followed for OHTN – History of RK • Variable IOP spikes RE – 3/1/16 visit – TA 29 • Suggestion of VF defect • OCT – probably normal...NOT • What do you do?

Arturo

• Being followed for OHTN

— History of RK

• Variable IOP spikes RE

— 3/1/16 visit – TA 29

• Suggestion of VF defect

• OCT—Thinning in the normal range

What do you do?

Latanoprost qhs RE started

107 108




57 yo Haitian Female

2009


- Exam for refractive needs computer glasses
- Has been considered a glaucoma suspect
- Father was blind from glaucoma
- VA: 20/20
- TA 19/16


109 110





111 112





113


4/13/21




• Observed -> No Treatment





115 116





117 118





119 120

Does she have glaucoma?

Does she need to be treated?

# Summary: The Pressure is On

- We recognize there are other factors besides IOP that influence the development/progression of glaucoma
  - We are gaining more and more understanding of these other factors
     OPP, Low BP, CSF pressure
- But for now IOP is still the only thing available to treat
- We have great technology to help us diagnose earlier and detect progression earlier
- And maybe even one day soon we will have a treatment that doesn't involve a drop, laser, or taking a medication